de Jong EM - Search Results

1

Epicutaneous application of leukotriene B4 induces patterns of tenascin and a heparan sulfate proteoglycan epitope that are typical for psoriatic lesions.

Seyger MM, van Pelt JP, van den Born J, Latijnhouwers MA, de Jong EM. Seyger MM, et al. Among authors: de jong em. Arch Dermatol Res. 1997 May;289(6):331-6. doi: 10.1007/s004030050200. Arch Dermatol Res. 1997. PMID: 9209678 Free article.

2

The inter-relation between inflammation and epidermal proliferation in normal skin following epicutaneous application of leukotriene-B4--an immunohistochemical study.

de Jong EM, van Erp PE, van Vlijmen IM, van de Kerkhof PC. de Jong EM, et al. Clin Exp Dermatol. 1992 Nov;17(6):413-20. doi: 10.1111/j.1365-2230.1992.tb00249.x. Clin Exp Dermatol. 1992. PMID: 1336720

3

Topical application of dithranol on normal skin induces epidermal hyperproliferation and increased Ks8.12 binding.

de Zwart AJ, de Jong EM, van de Kerkhof PC. de Zwart AJ, et al. Among authors: de jong em. Skin Pharmacol. 1992;5(1):34-40. doi: 10.1159/000211015. Skin Pharmacol. 1992. PMID: 1374264

4

Topical application of 13-cis-retinoic acid in the treatment of chronic plaque psoriasis.

Bischoff R, De Jong EM, Rulo HF, Sendagorta E, Czarnetzki BM, Van de Kerkhof PC. Bischoff R, et al. Among authors: de jong em. Clin Exp Dermatol. 1992 Jan;17(1):9-12. doi: 10.1111/j.1365-2230.1992.tb02523.x. Clin Exp Dermatol. 1992. PMID: 1424269 Clinical Trial.

5

Markers for proliferation and keratinization in the margin of the active psoriatic lesion.

de Mare S, de Jong E, Van Erp PE, Van de Kerkhof PC. de Mare S, et al. Br J Dermatol. 1990 Apr;122(4):469-75. doi: 10.1111/j.1365-2133.1990.tb14723.x. Br J Dermatol. 1990. PMID: 1692474

6

Clinical and biochemical effects of an oral leukotriene biosynthesis inhibitor (MK886) in psoriasis.

de Jong EM, van Vlijmen IM, Scholte JC, Buntinx A, Friedman B, Tanaka W, van de Kerkhof PC. de Jong EM, et al. Skin Pharmacol. 1991;4(4):278-85. doi: 10.1159/000210962. Skin Pharmacol. 1991. PMID: 1724166 Clinical Trial.

7

Keratin 17: a useful marker in anti-psoriatic therapies.

de Jong EM, van Vlijmen IM, van Erp PE, Ramaekers FC, Troyanovski SM, van de Kerkhof PC. de Jong EM, et al. Arch Dermatol Res. 1991;283(7):480-2. doi: 10.1007/BF00371788. Arch Dermatol Res. 1991. PMID: 1724898 No abstract available.

8

Simultaneous assessment of inflammation and epidermal proliferation in psoriatic plaques during long-term treatment with the vitamin D3 analogue MC903: modulations and interrelations.

de Jong EM, van de Kerkhof PC. de Jong EM, et al. Br J Dermatol. 1991 Mar;124(3):221-9. doi: 10.1111/j.1365-2133.1991.tb00565.x. Br J Dermatol. 1991. PMID: 2018728 Clinical Trial.

9

Effects of topical treatment with budesonide on parameters for epidermal proliferation, keratinization and inflammation in psoriasis.

de Jong EM, Ferrier CM, de Zwart A, Wauben-Penris PJ, Korstanje C, van de Kerkhof PC. de Jong EM, et al. Among authors: de zwart a. J Dermatol Sci. 1995 May;9(3):185-94. doi: 10.1016/0923-1811(94)00376-p. J Dermatol Sci. 1995. PMID: 8664216 Clinical Trial.

10

Epidermal differentiation characteristics of the psoriatic plaque during treatment with calcipotriol.

van der Vleuten CJ, de Jong EM, van de Kerkhof PC. van der Vleuten CJ, et al. Among authors: de jong em. Arch Dermatol Res. 1996 Jun;288(7):366-72. doi: 10.1007/BF02507105. Arch Dermatol Res. 1996. PMID: 8818184 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

333 results

Search Page

Filters